These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 20876113)

  • 21. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function.
    Udagawa N; Takahashi N; Yasuda H; Mizuno A; Itoh K; Ueno Y; Shinki T; Gillespie MT; Martin TJ; Higashio K; Suda T
    Endocrinology; 2000 Sep; 141(9):3478-84. PubMed ID: 10965921
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bone Remodeling and the Role of TRAF3 in Osteoclastic Bone Resorption.
    Boyce BF; Li J; Xing L; Yao Z
    Front Immunol; 2018; 9():2263. PubMed ID: 30323820
    [TBL] [Abstract][Full Text] [Related]  

  • 23. WHI-131 Promotes Osteoblast Differentiation and Prevents Osteoclast Formation and Resorption in Mice.
    Cheon YH; Kim JY; Baek JM; Ahn SJ; Jun HY; Erkhembaatar M; Kim MS; Lee MS; Oh J
    J Bone Miner Res; 2016 Feb; 31(2):403-15. PubMed ID: 26255791
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Emodin regulates bone remodeling by inhibiting osteoclastogenesis and stimulating osteoblast formation.
    Kim JY; Cheon YH; Kwak SC; Baek JM; Yoon KH; Lee MS; Oh J
    J Bone Miner Res; 2014 Jul; 29(7):1541-53. PubMed ID: 25832436
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Secreted frizzled-related protein-1 inhibits RANKL-dependent osteoclast formation.
    Häusler KD; Horwood NJ; Chuman Y; Fisher JL; Ellis J; Martin TJ; Rubin JS; Gillespie MT
    J Bone Miner Res; 2004 Nov; 19(11):1873-81. PubMed ID: 15476588
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of geranylgeranoic acid in bone: induction of osteoblast differentiation and inhibition of osteoclast formation.
    Wang X; Wu J; Shidoji Y; Muto Y; Ohishi N; Yagi K; Ikegami S; Shinki T; Udagawa N; Suda T; Ishimi Y
    J Bone Miner Res; 2002 Jan; 17(1):91-100. PubMed ID: 11771673
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ST2 regulates bone loss in a site-dependent and estrogen-dependent manner.
    Macari S; Madeira MFM; Lima ILA; Pereira TSF; Dias GJ; Cirelli JA; de Molon RS; Fukada SY; Szawka RE; Garlet GP; Teixeira MM; Silva TA
    J Cell Biochem; 2018 Nov; 119(10):8511-8521. PubMed ID: 30011081
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Apolipoprotein E plays crucial roles in maintaining bone mass by promoting osteoblast differentiation via ERK1/2 pathway and by suppressing osteoclast differentiation via c-Fos, NFATc1, and NF-κB pathway.
    Noguchi T; Ebina K; Hirao M; Otsuru S; Guess AJ; Kawase R; Ohama T; Yamashita S; Etani Y; Okamura G; Yoshikawa H
    Biochem Biophys Res Commun; 2018 Sep; 503(2):644-650. PubMed ID: 29906458
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Peripheral cannabinoid receptor, CB2, regulates bone mass.
    Ofek O; Karsak M; Leclerc N; Fogel M; Frenkel B; Wright K; Tam J; Attar-Namdar M; Kram V; Shohami E; Mechoulam R; Zimmer A; Bab I
    Proc Natl Acad Sci U S A; 2006 Jan; 103(3):696-701. PubMed ID: 16407142
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Calcitonin Induces Bone Formation by Increasing Expression of Wnt10b in Osteoclasts in Ovariectomy-Induced Osteoporotic Rats.
    Hsiao CY; Chen TH; Chu TH; Ting YN; Tsai PJ; Shyu JF
    Front Endocrinol (Lausanne); 2020; 11():613. PubMed ID: 33013696
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rosmarinic acid exerts an antiosteoporotic effect in the RANKL-induced mouse model of bone loss by promotion of osteoblastic differentiation and inhibition of osteoclastic differentiation.
    Lee JW; Asai M; Jeon SK; Iimura T; Yonezawa T; Cha BY; Woo JT; Yamaguchi A
    Mol Nutr Food Res; 2015 Mar; 59(3):386-400. PubMed ID: 25380345
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MicroRNA-29a represses osteoclast formation and protects against osteoporosis by regulating PCAF-mediated RANKL and CXCL12.
    Lian WS; Ko JY; Chen YS; Ke HJ; Hsieh CK; Kuo CW; Wang SY; Huang BW; Tseng JG; Wang FS
    Cell Death Dis; 2019 Sep; 10(10):705. PubMed ID: 31543513
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of Osteoblast Gi Signaling in Age-Related Bone Loss in Female Mice.
    Millard SM; Wang L; Wattanachanya L; O'Carroll D; Fields AJ; Pang J; Kazakia G; Lotz JC; Nissenson RA
    Endocrinology; 2017 Jun; 158(6):1715-1726. PubMed ID: 28407060
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Histological Effects of the Combined Administration of Eldecalcitol and a Parathyroid Hormone in the Metaphyseal Trabeculae of Ovariectomized Rats.
    Hasegawa T; Yamamoto T; Sakai S; Miyamoto Y; Hongo H; Qiu Z; Abe M; Takeda S; Oda K; de Freitas PHL; Li M; Endo K; Amizuka N
    J Histochem Cytochem; 2019 Mar; 67(3):169-184. PubMed ID: 30311820
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Osteoblastic responses to TGF-beta during bone remodeling.
    Erlebacher A; Filvaroff EH; Ye JQ; Derynck R
    Mol Biol Cell; 1998 Jul; 9(7):1903-18. PubMed ID: 9658179
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Arctiin abrogates osteoclastogenesis and bone resorption via suppressing RANKL-induced ROS and NFATc1 activation.
    Chen D; Ye Z; Wang C; Wang Q; Wang H; Kuek V; Wang Z; Qiu H; Yuan J; Kenny J; Yang F; He J; Liu Y; Wang G; Zhang M; Zhang G; Wang J; Chen P; Xu J
    Pharmacol Res; 2020 Sep; 159():104944. PubMed ID: 32454224
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intracellular calcium and protein kinase C mediate expression of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in osteoblasts.
    Takami M; Takahashi N; Udagawa N; Miyaura C; Suda K; Woo JT; Martin TJ; Nagai K; Suda T
    Endocrinology; 2000 Dec; 141(12):4711-9. PubMed ID: 11108286
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cumambrin A prevents OVX-induced osteoporosis
    Zhou L; Liu Q; Hong G; Song F; Zhao J; Yuan J; Xu J; Tan RX; Tickner J; Gu Q; Xu J
    FASEB J; 2019 Jun; 33(6):6726-6735. PubMed ID: 30807230
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Osteogenic growth peptide effects on primary human osteoblast cultures: potential relevance for the treatment of glucocorticoid-induced osteoporosis.
    Spreafico A; Frediani B; Capperucci C; Leonini A; Gambera D; Ferrata P; Rosini S; Di Stefano A; Galeazzi M; Marcolongo R
    J Cell Biochem; 2006 Jul; 98(4):1007-20. PubMed ID: 16795077
    [TBL] [Abstract][Full Text] [Related]  

  • 40. DDR2 (discoidin domain receptor 2) suppresses osteoclastogenesis and is a potential therapeutic target in osteoporosis.
    Zhang Y; Su J; Wu S; Teng Y; Yin Z; Guo Y; Li J; Li K; Yao L; Li X
    Sci Signal; 2015 Mar; 8(369):ra31. PubMed ID: 25805889
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.